Reimbursed Care Access in Australia

Australia’s Therapeutic Goods Administration (TGA) amended the Poisons Standard to permit prescribing of psilocybin preparations by psychiatrists who are specifically authorised under the TGA’s Authorised Prescriber scheme, effective 1 July 2023; access is limited to the treatment of treatment‑resistant depression under strict protocols and local Human Research Ethics Committee / Authorised Prescriber approvals. #

Prescribing pathway and reimbursement: no TGA‑evaluated, registered product containing psilocybin (i.e., no ARTG‑listed registered psilocybin medicine) had received general registration at time of rescheduling; this means psychiatrists supply specified (unapproved) medicines under the Authorised Prescriber scheme or via other special access pathways rather than by referencing a registered product, and public reimbursement (PBS) is not available for psilocybin treatments generally. Access is therefore delivered largely in private clinics or within approved clinical/research programs and typically requires out‑of‑pocket payment or philanthropic/subsidy support arranged by clinics or suppliers. #

Regulatory controls and clinical governance: the Delegate limited prescribing to authorised psychiatrists because of patient vulnerability during psychedelic‑assisted psychotherapy; psychiatrists must satisfy TGA and ethics committee requirements and are expected to implement robust safety protocols, clinician training and monitoring. State/territory criminal laws and import controls still apply to non‑authorised possession or supply; for uses outside the authorised indications, psilocybin remains schedule 9 (prohibited) except in approved trials. #

MDMA (3,4‑methylenedioxy‑methamphetamine) was reclassified in the Poisons Standard so that psychiatrists authorised under the TGA Authorised Prescriber scheme can prescribe MDMA for post‑traumatic stress disorder (PTSD) from 1 July 2023; outside those narrow-authorised uses MDMA remains schedule 9 (prohibited) and supply is largely restricted to approved clinical trials. #

Reimbursement and products: as with psilocybin, there were (and continue to be) no widely registered, TGA‑approved finished MDMA medicines available for general prescription at the time of down‑scheduling; access is therefore via Authorised Prescriber approvals supplying unapproved medicines, or within clinical trials and specialist clinics that may charge patients directly. There has been active commercial importation/distribution activity (private charity and supplier arrangements) to supply authorised clinics, but public subsidy (PBS) for MDMA‑assisted therapy is not an established pathway, so most treatments are privately funded. #

Clinical governance: the TGA and expert committees emphasised psychiatrist authorisation, ethics committee oversight, and the need for clinician training and safety protocols; professional colleges continue to debate training standards and implementation (state/territory requirements may influence service delivery locations). #

Esketamine (Spravato® nasal spray) is approved by the TGA for treatment‑resistant depression (Major Depressive Disorder not adequately responsive to at least two different antidepressants) — registration decision published 5 March 2021 and ARTG registration on 9 March 2021. #

Reimbursement and access: Janssen’s Spravato has been submitted to and considered by PBAC/PBS processes; Spravato is listed on the Pharmaceutical Benefits Scheme (PBS) with authority‑required access for treatment‑resistant major depression effective 1 May 2025, which establishes a subsidised patient co‑payment and formal prescriber/authority pathways (clinics must meet supervision/administration requirements). PBS listing means eligible patients meeting PBS authority criteria can access Spravato at the subsidised price rather than full private pricing, though clinic administration fees and private clinic visit costs may still apply. # #

Delivery model and clinical governance: Spravato is a restricted medication that must be administered in certified treatment centres under clinical supervision; eligibility criteria mirror treatment‑resistant depression definitions (failure of ≥2 antidepressant trials) and prescribers must follow risk‑management and monitoring requirements. Public hospital services may deliver treatments in some jurisdictions, but much delivery has been through private specialist clinics — PBS listing reduces direct drug cost but not necessarily associated clinic/service fees. #

Ketamine (racemic ketamine), used off‑label for severe depression and as an anaesthetic, is widely used in Australia in hospital and private clinic settings for treatment‑resistant depression and palliative care, but off‑label use means it is prescribed outside formal indications and without PBS subsidy for psychiatric indications in the same way as an approved antidepressant. Hospital inpatient and public health delivery of ketamine for anaesthesia is routine and publicly funded in that context, but outpatient psychiatric ketamine infusions or intramuscular/intravenous regimens are typically private, out‑of‑pocket services unless provided under a funded clinical service or trial. #

Regulatory and reimbursement nuance: because ketamine is a registered anaesthetic/analgesic product for specific indications, psychiatrists and other clinicians sometimes prescribe it off‑label for depression under established clinical governance frameworks; reimbursement for off‑label indications through public insurers (Medicare/PBS) is limited and episodic — Medicare and PBS generally do not subsidise off‑label drug use unless captured under a specific program or clinical trial. Patients accessing ketamine infusions for depression should expect private clinic fees and variable Medicare rebate treatment for professional services but not a PBS‑subsidised drug price in most outpatient models. (See TGA scheduling and usual pathways for unapproved/off‑label use.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (and preparations containing DMT such as ayahuasca) remain subject to federal import and criminal offences; unlawful importation, possession or supply attracts severe penalties under the Criminal Code and state/territory laws. # #

Currently classified as a strictly controlled substance under national/state drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, importation or supply outside sanctioned clinical trials or authorised programs is an offence under Commonwealth and state legislation. #

Currently classified as a strictly controlled substance under national drug scheduling laws with no authorised medical use outside of approved clinical research; importation and administration require specific licensing and are otherwise prohibited. There is no routine medical/insured pathway for ibogaine in Australia; Australians seeking ibogaine treatment commonly travel overseas. # #

Currently classified as a strictly controlled substance under national drug scheduling laws (because it contains DMT) with no authorised medical or religious exemption for importation or use in most Australian jurisdictions; possession or importation of ayahuasca preparations is a criminal offence except as permitted in tightly regulated research or authorised medical frameworks. There are no general reimbursement or public access pathways. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside approved clinical research. Mescaline (and mescaline‑containing cactus preparations) are prohibited to possess, import or supply without explicit licensing for research/therapeutic trials. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside approved clinical research. Novel phenethylamine psychedelics in the 2C family are prohibited and not part of authorised therapeutic frameworks in Australia. #